Tamoxifen as a Selective Estrogen Receptor Modulator: Advances in Breast Cancer Therapeutics

Author(s)	Yogita Vaishnav, Prof. Umme Roman Shaikh
Country	India
Abstract	Tamoxifen is a cornerstone endocrine therapy used primarily in the management and prevention of estrogen receptor–positive breast cancer. As a selective estrogen receptor modulator, it blocks estrogen-driven tumor growth in breast tissue while maintaining partial estrogen-like activity in other organs. This dual action contributes to its clinical effectiveness as well as to certain adverse effects. Evidence from decades of use shows that tamoxifen reduces disease recurrence, lowers the risk of developing cancer in the opposite breast, and provides meaningful survival benefits across a wide range of patient populations. Its oral administration and long-term safety record have supported its use in both treatment and risk-reduction settings. However, concerns such as thromboembolic events, menopausal symptoms, and endometrial changes require careful monitoring. Ongoing research aims to better understand resistance mechanisms and individual variability in response, helping to refine how tamoxifen is used in modern breast cancer.
Field	Medical / Pharmacy
Published In	Volume 7, Issue 6, November-December 2025
Published On	2025-11-27
DOI	https://doi.org/10.36948/ijfmr.2025.v07i06.62153
Short DOI	https://doi.org/hbdsmj

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research